Ohcanbohtosat - Michael Robbins

  • Čájehuvvo 1 - 19 / 19
Aiddostahte ozu
  1. 1
    Repair of DNA studied with a nuclease specific for UV-induced lesions.

    Repair of DNA studied with a nuclease specific for UV-induced lesions. Dahkki Bernard S. Strauss, T. Searashi, Michael Robbins

    Almmustuhtton 1966
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    Immune Cell Inhibition by SLAMF7 Is Mediated by a Mechanism Requiring Src Kinases, CD45, and SHIP-1 That Is Defective in Multiple Myeloma Cells

    Immune Cell Inhibition by SLAMF7 Is Mediated by a Mechanism Requiring Src Kinases, CD45, and SHIP-1 That Is Defective in Multiple Myeloma Cells Dahkki Huaijian Guo, Mario‐Ernesto Cruz‐Munoz, Ning Wu, Michael Robbins, André Veillette

    Almmustuhtton 2014
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  3. 3
    Violent and Nonviolent Death Tolls for the Gaza War: New Primary Evidence

    Violent and Nonviolent Death Tolls for the Gaza War: New Primary Evidence Dahkki Michael Spagat, Jon Pedersen, Khalil Shikaki, Michael Robbins, Eran Bendavid, Håvard Hegre, Deberati Guha-Sapir

    Almmustuhtton 2025
    Viečča ollesdeavstta
    Pré-impressão
    Lasit oiddohiidda
    Furkejuvvon:
  4. 4
    Molecular Indices of Neuronal and Glial Plasticity in the Hippocampal Formation in a Rodent Model of Age-Induced Spatial Learning Impairment

    Molecular Indices of Neuronal and Glial Plasticity in the Hippocampal Formation in a Rodent Model of Age-Induced Spatial Learning Impairment Dahkki Kimio Sugaya, Michael Chouinard, R. Greene, Michael Robbins, David Personett, Caroline Kent, Michela Gallagher, Michael McKinney

    Almmustuhtton 1996
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  5. 5
    Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways

    Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways Dahkki Balaji Balasa, Rui Yun, Nicole A. Belmar, Melvin Fox, Debra T. Chao, Michael Robbins, Gary C. Starling, Audie Rice

    Almmustuhtton 2014
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  6. 6
    Assembly and Regulation of the CD40 Receptor Complex in Human B Cells

    Assembly and Regulation of the CD40 Receptor Complex in Human B Cells Dahkki Michelle Kuhne, Michael Robbins, John Hambor, Matthew F. Mackey, Yoko Kosaka, Toshihide Nishimura, Jason P. Gigley, Randolph J. Noelle, David M. Calderhead

    Almmustuhtton 1997
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  7. 7
    The CD28 and CTLA-4 Receptors Associate with the Serine/Threonine Phosphatase PP2A

    The CD28 and CTLA-4 Receptors Associate with the Serine/Threonine Phosphatase PP2A Dahkki Ellen Chuang, Timothy S. Fisher, Rodney Morgan, Michael Robbins, James M. Duerr, Matthew G. Vander Heiden, Joseph P. Gardner, John Hambor, Mark J. Neveu, Craig B. Thompson

    Almmustuhtton 2000
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  8. 8
    The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and –independent mechanisms

    The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and –independent mechanisms Dahkki Tatiana Pazina, Ashley M. James, Alexander W. MacFarlane, Natalie Bezman, Karla A. Henning, Christine Bee, Robert F. Graziano, Michael Robbins, Adam D. Cohen, Kerry S. Campbell

    Almmustuhtton 2017
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  9. 9
    Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma

    Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma Dahkki Tatiana Pazina, Alexander W. MacFarlane, Luca Bernabei, Essel Dulaimi, Rebecca E. Kotcher, Clinton Yam, Natalie Bezman, Michael Robbins, Eric A. Ross, Kerry S. Campbell, Adam D. Cohen

    Almmustuhtton 2021
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  10. 10
    Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma

    Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma Dahkki Tatiana Pazina, Ashley M. James, Kimberly B. Colby, Yibin Yang, Andrew N. Gale, Amy Jhatakia, Alper Y. Kearney, Robert F. Graziano, Natalie Bezman, Michael Robbins, Adam D. Cohen, Kerry S. Campbell

    Almmustuhtton 2019
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  11. 11
    Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened

    Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened Dahkki Michael J. Munchhof, Qifang Li, Andrei Shavnya, Gary Borzillo, Tracey Boyden, Christopher S. Jones, Susan LaGreca, Luis Martinez-Alsina, Nandini C. Patel, Kathleen Pelletier, Larry A. Reiter, Michael Robbins, George T. Tkalcevic

    Almmustuhtton 2011
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  12. 12
    PD-1 blockade enhances elotuzumab efficacy in mouse tumor models

    PD-1 blockade enhances elotuzumab efficacy in mouse tumor models Dahkki Natalie Bezman, Amy Jhatakia, Alper Y. Kearney, Ty Brender, Mark Maurer, Karla A. Henning, Misty R. Jenkins, Amy J. Rogers, Paul J. Neeson, Alan J. Korman, Michael Robbins, Robert F. Graziano

    Almmustuhtton 2017
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  13. 13
    Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab

    Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab Dahkki Ahmed T. Kurdi, Siobhan Glavey, Natalie Bezman, Amy Jhatakia, Jennifer L. Guerriero, Salomon Manier, Michele Moschetta, Yuji Mishima, Aldo M. Roccaro, Alexandre Detappe, Chia‐Jen Liu, Antonio Sacco, Daisy Huynh, Yu‐Tzu Tai, Michael Robbins, Jamil Azzi, Irene M. Ghobrial

    Almmustuhtton 2018
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  14. 14
    Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM

    Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM Dahkki Andrzej Jakubowiak, Massimo Offidani, Brigitte Pegourié, Javier de la Rubia, Laurent Garderet, Kamel Laribi, Alberto Bosi, Roberto Marasca, Jacob P. Laubach, Ann Mohrbacher, Angelo Michele Carella, Anil Singhal, L. Claire Tsao, Mark Lynch, Eric Bleickardt, Ying‐Ming Jou, Michael Robbins, Antonio Palumbo

    Almmustuhtton 2016
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  15. 15
    Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

    Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma Dahkki Meletios Α. Dimopoulos, Dominik Dytfeld, Sebastian Grosicki, Philippe Moreau, Naoki Takezako, Mitsuo Hori, Xavier Leleu, Richard LeBlanc, Kenshi Suzuki, Marc S. Raab, Paul G. Richardson, Mihaela Popa McKiver, Ying-Ming Jou, Suresh G. Shelat, Michael Robbins, Brian T. Rafferty, Jesús F. San Miguel

    Almmustuhtton 2018
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  16. 16
    A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma

    A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma Dahkki Irene M. Ghobrial, Chia‐Jen Liu, Robert Redd, Raymond P. Perez, Rachid Baz, Oksana Zavidij, Romanos Sklavenitis‐Pistofidis, Paul G. Richardson, Kenneth C. Anderson, Jacob P. Laubach, Patrick Henrick, Alexandra Savell, Kaitlen Reyes, Kalvis Hornburg, Stacey Chuma, Peter Sabbatini, Michael Robbins, Pamela S. Becker

    Almmustuhtton 2019
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  17. 17
    The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications

    The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications Dahkki Kenneth C. Anderson, Daniel Auclair, Gary J. Kelloff, Caroline C. Sigman, Hervé Avet‐Loiseau, Ann T. Farrell, Nicole Gormley, Shaji Kumar, Ola Landgren, Nikhil C. Munshi, Michèle Cavo, Faith E. Davies, Alessandra Di Bacco, Jennifer S. Dickey, Steven Gutman, Howard R. Higley, Mohamad A. Hussein, J. Milburn Jessup, Ilan R. Kirsch, Richard F. Little, Robert D. Loberg, Jens G. Lohr, Lata Mukundan, James Omel, Trevor J. Pugh, Gregory H. Reaman, Michael Robbins, A. Kate Sasser, Nancy Valente, Elena Zamagni

    Almmustuhtton 2017
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  18. 18
    Clinical Genetic Testing for Patients With Autism Spectrum Disorders

    Clinical Genetic Testing for Patients With Autism Spectrum Disorders Dahkki Yiping Shen, Kira A. Dies, Ingrid A. Holm, Carolyn Bridgemohan, Magdi M. Sobeih, Elizabeth Caronna, Karen J. Miller, Jean A. Frazier, Iris Silverstein, Jonathan Picker, Laura Weissman, Peter Raffalli, Shafali Jeste, Laurie Demmer, Heather Peters, Stephanie J. Brewster, Sara J. Kowalczyk, Beth Rosen‐Sheidley, Caroline McGowan, Andrew W. Duda, Sharyn A. Lincoln, Kathryn Lowe, Alison Schonwald, Michael Robbins, Fuki M. Hisama, Robert R. Wolff, Ronald E. Becker, Ramzi Nasir, David K. Urion, Jeff M. Milunsky, Leonard Rappaport, James F. Gusella, Christopher A. Walsh, Bai-Lin Wu, David T. Miller

    Almmustuhtton 2010
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  19. 19
    Copy number variation plays an important role in clinical epilepsy

    Copy number variation plays an important role in clinical epilepsy Dahkki Heather E. Olson, Yiping Shen, Jennifer Avallone, Beth Rosen Sheidley, Rebecca Pinsky, Ann M. Bergin, Gerard T. Berry, Frank H. Duffy, Yaman Z. Ekşioğlu, David J. Harris, Fuki M. Hisama, Eugenia Ho, Mira Irons, Christina M. Jacobsen, Philip James, Sanjeev V. Kothare, Omar Khwaja, Jonathan O. Lipton, Tobias Loddenkemper, Jennifer A. Markowitz, Kiran Maski, J. Thomas Megerian, Edward Neilan, Peter C. Raffalli, Michael Robbins, Amy E. Roberts, Eugene Roe, Caitlin K. Rollins, Mustafa Şahin, Dean Sarco, Alison Schonwald, Sharon E. Smith, Janet S. Soul, Joan M. Stoler, Masanori Takeoka, Wen‐Hann Tan, Alcy Torres, Peter T. Tsai, David K. Urion, Laura Weissman, Robert R. Wolff, Bai‐Lin Wu, David T. Miller, Annapurna Poduri

    Almmustuhtton 2014
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: